drugtargetreview.com23h
Promising Alzheimer’s drug earns FDA fast-track designation
Johnson & Johnson is advancing Alzheimer’s research through precision medicine, focusing on tau-targeting therapies like ...
drugtargetreview.com2d
ITM-11 boosts survival in neuroendocrine tumour trial
A new targeted radiotherapy offers hope for patients with rare neuroendocrine tumours, demonstrating a significant improvement in progression-free survival in a key clinical trial. ITM Isotope ...
drugtargetreview.com4d
Restoring the gut: VE303’s strategy for C. diff relief
Learn about VE303, a potential first-in-class Live Biotherapeutic Product for preventing recurrent Clostridioides difficile ...
drugtargetreview.com4d
AI designs peptides for ‘undruggable’ diseases
Discover the groundbreaking AI-based platform that designs peptides to target and destroy previously 'undruggable' ...
drugtargetreview.com5d
Coherus announces positive Phase II results for liver cancer treatment
Coherus BioSciences shared final data from its Phase II trial of casdozokitug, showing a 17.2 percent complete response rate in liver cancer patients. Coherus BioSciences announced the final data from ...
drugtargetreview.com6d
Glox Therapeutics secures £500K to develop antibiotics for cystic fibrosis
Glox Therapeutics has received a portion of a £3 million fund to combat antimicrobial resistance in cystic fibrosis patients. The CF AMR Syndicate, which combines expertise from various sectors ...
drugtargetreview.com6d
Cilta-cel: A new era in multiple myeloma treatment
New cell therapy, Cilta-cel, shows promise in the treatment of multiple myeloma, providing a personalised approach with the ...